Pfizer has lauded its clinical development and vaccine manufacturing capabilities as it hopes to produce a total of 4 billion doses of Comirnaty by the end of 2022.  Through its partnership with BioNTech, Pfizer became the first company to bring a messenger RNA-based product to market, namely the COVID-19 vaccine Comirnaty (BNT162b2), which received emergency use approval in December 2020.  This week, Pfizer told shareholders during its Q4 2021 earnings call that the jab has generated $36.8 billion sales worldwide for…